<![CDATA[Deep Vein Thromboembolism (DVT) is a form of venous thromboembolism requiring anticoagulant therapy to prevent complications. Treatment effectiveness is assessed through therapeutic target achievement based on Activated Partial Thromboplastin Time (APTT) for heparin, Prothrombin Time/International Normalized Ratio (PT/INR) for warfarin, and dose appropriateness for other anticoagulants. This study aimed to evaluate therapeutic target achievement and dose appropriateness in DVT patients receiving anticoagulant therapy at the Inpatient Unit of X Hospital, Pekanbaru, in 2024. This descriptive observational study used a cross-sectional approach with retrospective medical record data. A total of 45 patients were selected using total sampling. Heparin was the most frequently used anticoagulant (22 patients; 48.89%), followed by warfarin (10; 22.22%), rivaroxaban (5; 11.11%), fondaparinux (5; 11.11%), and enoxaparin (3; 6.67%). Therapeutic targets were achieved by 27 patients (84.38%), while 5 patients (15.62%) did not achieve the target. Regarding dose appropriateness, 8 patients (61.53%) received appropriate doses, while 5 patients (38.46%) received inappropriate doses. In conclusion, most DVT patients achieved therapeutic targets and received appropriate doses. Monitoring APTT, PT/INR, and dose appropriateness remains important to support the effectiveness and safety of anticoagulant therapy.]]>
